CN102712677B - 脂肽组合物和相关方法 - Google Patents

脂肽组合物和相关方法 Download PDF

Info

Publication number
CN102712677B
CN102712677B CN201080062122.3A CN201080062122A CN102712677B CN 102712677 B CN102712677 B CN 102712677B CN 201080062122 A CN201080062122 A CN 201080062122A CN 102712677 B CN102712677 B CN 102712677B
Authority
CN
China
Prior art keywords
daptomycin
formulation
solid
solid drug
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080062122.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102712677A (zh
Inventor
S.孙
G.纳伊克
S.奥康纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qiubi Munster Pharmaceutical LLC
Original Assignee
Cubist Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44060422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102712677(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals LLC filed Critical Cubist Pharmaceuticals LLC
Priority to CN201810651754.1A priority Critical patent/CN108785654A/zh
Publication of CN102712677A publication Critical patent/CN102712677A/zh
Application granted granted Critical
Publication of CN102712677B publication Critical patent/CN102712677B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201080062122.3A 2009-11-23 2010-11-23 脂肽组合物和相关方法 Active CN102712677B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810651754.1A CN108785654A (zh) 2009-11-23 2010-11-23 脂肽组合物和相关方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23
US61/263,784 2009-11-23
PCT/US2010/057910 WO2011063419A2 (en) 2009-11-23 2010-11-23 Lipopeptide compositions and related methods

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201410208415.8A Division CN104056250A (zh) 2009-11-23 2010-11-23 脂肽组合物和相关方法
CN201810651754.1A Division CN108785654A (zh) 2009-11-23 2010-11-23 脂肽组合物和相关方法

Publications (2)

Publication Number Publication Date
CN102712677A CN102712677A (zh) 2012-10-03
CN102712677B true CN102712677B (zh) 2015-06-03

Family

ID=44060422

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201080062122.3A Active CN102712677B (zh) 2009-11-23 2010-11-23 脂肽组合物和相关方法
CN201810651754.1A Pending CN108785654A (zh) 2009-11-23 2010-11-23 脂肽组合物和相关方法
CN201410208415.8A Pending CN104056250A (zh) 2009-11-23 2010-11-23 脂肽组合物和相关方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201810651754.1A Pending CN108785654A (zh) 2009-11-23 2010-11-23 脂肽组合物和相关方法
CN201410208415.8A Pending CN104056250A (zh) 2009-11-23 2010-11-23 脂肽组合物和相关方法

Country Status (33)

Country Link
US (3) US8835382B2 (enExample)
EP (2) EP3417849A1 (enExample)
JP (3) JP6041673B2 (enExample)
CN (3) CN102712677B (enExample)
AR (2) AR079127A1 (enExample)
AU (1) AU2010321531C1 (enExample)
BR (1) BR112012012406B1 (enExample)
CA (1) CA2781666C (enExample)
CL (2) CL2012001336A1 (enExample)
CO (1) CO6541585A2 (enExample)
CR (1) CR20120271A (enExample)
CY (1) CY1120854T1 (enExample)
DK (1) DK2504353T4 (enExample)
DO (1) DOP2012000140A (enExample)
EC (1) ECSP12011939A (enExample)
ES (1) ES2686331T5 (enExample)
FI (1) FI2504353T4 (enExample)
HR (1) HRP20181380T4 (enExample)
HU (1) HUE039967T2 (enExample)
IL (1) IL219891B (enExample)
LT (1) LT2504353T (enExample)
MX (1) MX2012005993A (enExample)
NZ (1) NZ600118A (enExample)
PE (2) PE20151717A1 (enExample)
PL (1) PL2504353T5 (enExample)
PT (1) PT2504353T (enExample)
RS (1) RS57566B2 (enExample)
RU (1) RU2607526C2 (enExample)
SG (1) SG10201407724YA (enExample)
SI (1) SI2504353T2 (enExample)
TR (1) TR201812823T4 (enExample)
TW (2) TWI548414B (enExample)
WO (1) WO2011063419A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
JP5913367B2 (ja) 2011-01-05 2016-04-27 ホスピーラ インコーポレイテッド バンコマイシンの噴霧乾燥
MX2013013760A (es) * 2011-05-26 2014-01-08 Cubist Pharm Inc Composiciones de cb-183, 315 y metodos relacionados.
AU2013201937B8 (en) * 2012-01-12 2015-08-20 Celgene Corporation Romidepsin formulations and uses thereof
NO2887953T3 (enExample) * 2012-08-23 2018-03-10
PL4066849T3 (pl) 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
WO2018073269A1 (en) 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
US11759497B2 (en) 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
US12667545B2 (en) 2019-09-20 2026-06-30 Nivagen Pharmaceuticals, Inc. Lyophilized compositions of phenobarbital sodium salt
JP7582205B2 (ja) * 2019-12-26 2024-11-13 ニプロ株式会社 ダプトマイシンを含有する安定した凍結乾燥製剤
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц
WO2026111848A1 (en) 2024-11-21 2026-05-28 MAIA Pharmaceuticals, Inc. Daptomycin compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053330A2 (en) * 2000-01-20 2001-07-26 Cubist Pharmaceuticals, Inc. High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them
CN1592753A (zh) * 2000-12-18 2005-03-09 卡比斯特制药公司 制备纯化脂肽的方法
CN101330905A (zh) * 2005-11-18 2008-12-24 赛多斯有限责任公司 冻干方法和由此获得的产品

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
CN1051200A (zh) 1984-10-09 1991-05-08 伊莱利利公司 制备抗菌素a-21978c复合物或因子的方法
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) * 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
DE69031730T2 (de) 1990-01-26 1998-04-23 Hoechst Ag Neues Antibiotikum, Deoxymulündocandin, Verfahren zu seiner Produktion und Verwendung als Medikament
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (enExample) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) * 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
EP0640095B1 (en) 1992-04-20 1998-07-01 Abbott Laboratories Process for making vancomycin
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
HU230656B1 (hu) 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
CN1423656A (zh) 1999-12-15 2003-06-11 卡比斯特制药公司 作为抗菌剂的脂肽
AU2001267011B2 (en) * 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
WO2002059145A1 (en) 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重ｔ細胞エピトープポリペプチドの酢酸塩組成物
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20050027113A1 (en) 2001-08-06 2005-02-03 Miao Vivian Pak Woon Compositions and methods relating to the daptomycin biosynthetic gene cluster
ATE325140T1 (de) 2002-01-17 2006-06-15 Arkema Supramolekularpolymere
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−１１含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
EP1848413B1 (en) * 2005-02-14 2014-04-09 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
JP2008546429A (ja) 2005-05-31 2008-12-25 キュービスト ファーマシューティカルズ， インコーポレイテッド バイオフィルム処理およびカテーテル救出のためのダプトマイシン
EP1919449A2 (en) 2005-06-07 2008-05-14 Foamix Ltd. Antibiotic kit and composition and uses thereof
BRPI0715113A2 (pt) * 2006-07-26 2013-06-04 Sandoz Ag Sandoz Sa Sandoz Ltd formulaÇço de caspofungina
EP2084519B1 (en) 2006-10-10 2012-08-01 Los Alamos National Security, LLC X-ray fluorescence analysis method
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
EP2150537A4 (en) * 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
EP2170362B1 (en) 2007-06-26 2015-11-04 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
RU2517140C2 (ru) * 2007-10-25 2014-05-27 Новартис Аг Способ обработки упаковки с однократной дозой лекартвенного препарата
WO2009144739A1 (en) 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
WO2011019839A2 (en) 2009-08-12 2011-02-17 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
US8431539B2 (en) 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
US20110124551A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
WO2012061360A2 (en) 2010-11-01 2012-05-10 Rib-X Pharmaceuticals, Inc. Pharmaceutical compositions
JP6013364B2 (ja) 2010-12-23 2016-10-25 アルカーメス ファーマ アイルランド リミテッド マルチプルａｐｉローディングプロドラッグ
WO2012112319A1 (en) 2011-02-04 2012-08-23 Aegis Therapeutics, Llc Orally bioavailable peptide drug compositions and methods thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053330A2 (en) * 2000-01-20 2001-07-26 Cubist Pharmaceuticals, Inc. High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them
CN1592753A (zh) * 2000-12-18 2005-03-09 卡比斯特制药公司 制备纯化脂肽的方法
CN101330905A (zh) * 2005-11-18 2008-12-24 赛多斯有限责任公司 冻干方法和由此获得的产品

Also Published As

Publication number Publication date
US20160030577A1 (en) 2016-02-04
US8835382B2 (en) 2014-09-16
CN104056250A (zh) 2014-09-24
HRP20181380T4 (hr) 2023-11-10
RS57566B2 (sr) 2023-12-29
PE20151717A1 (es) 2015-11-19
SI2504353T1 (sl) 2018-10-30
SI2504353T2 (sl) 2023-11-30
BR112012012406A2 (pt) 2019-12-03
AU2010321531A2 (en) 2014-10-30
EP2504353B2 (en) 2023-09-13
JP2016147874A (ja) 2016-08-18
PE20121517A1 (es) 2012-11-26
RS57566B1 (sr) 2018-10-31
ES2686331T5 (es) 2024-03-27
CO6541585A2 (es) 2012-10-16
DK2504353T4 (da) 2023-11-20
SG10201407724YA (en) 2014-12-30
JP6041673B2 (ja) 2016-12-14
US9662397B2 (en) 2017-05-30
AR079127A1 (es) 2011-12-28
US20120270772A1 (en) 2012-10-25
CN102712677A (zh) 2012-10-03
EP2504353A4 (en) 2014-04-02
JP2017075186A (ja) 2017-04-20
CL2015002412A1 (es) 2016-02-05
TWI548414B (zh) 2016-09-11
CY1120854T1 (el) 2019-12-11
NZ600118A (en) 2014-08-29
TW201703791A (zh) 2017-02-01
ECSP12011939A (es) 2012-07-31
CA2781666A1 (en) 2011-05-26
PL2504353T3 (pl) 2018-11-30
AU2010321531B2 (en) 2016-11-03
PL2504353T5 (pl) 2023-11-20
ES2686331T3 (es) 2018-10-17
CN108785654A (zh) 2018-11-13
RU2607526C2 (ru) 2017-01-10
WO2011063419A2 (en) 2011-05-26
PT2504353T (pt) 2018-10-18
CL2012001336A1 (es) 2012-10-05
IL219891B (en) 2018-01-31
US20140364380A1 (en) 2014-12-11
TR201812823T4 (tr) 2019-02-21
CR20120271A (es) 2012-08-01
AR123846A2 (es) 2023-01-18
RU2012126076A (ru) 2013-12-27
EP2504353B1 (en) 2018-07-11
AU2010321531A1 (en) 2012-06-14
AU2010321531C1 (en) 2020-10-01
LT2504353T (lt) 2018-09-25
HUE039967T2 (hu) 2019-02-28
JP2013511557A (ja) 2013-04-04
DOP2012000140A (es) 2012-10-30
FI2504353T4 (fi) 2023-11-30
BR112012012406B1 (pt) 2021-11-16
JP6239167B2 (ja) 2017-11-29
EP2504353A2 (en) 2012-10-03
US9138456B2 (en) 2015-09-22
DK2504353T3 (en) 2018-09-10
WO2011063419A3 (en) 2011-10-13
JP6088681B2 (ja) 2017-03-01
HRP20181380T1 (hr) 2018-10-19
EP3417849A1 (en) 2018-12-26
TW201141506A (en) 2011-12-01
TWI606838B (zh) 2017-12-01
MX2012005993A (es) 2012-11-23
IL219891A0 (en) 2012-07-31
CA2781666C (en) 2017-02-21

Similar Documents

Publication Publication Date Title
CN102712677A (zh) 脂肽组合物和相关方法
JP5914486B2 (ja) カスポファンギン組成物
JP2013511557A5 (enExample)
JP4142149B2 (ja) バンコマイシンの凍結乾燥製剤
AU2021227095B2 (en) Daptomycin formulation
WO2014182368A2 (en) Voriconazole formulations
HK1176367A (en) Lipopeptide compositions and related methods
HK1176367B (en) Lipopeptide compositions and related methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP03 Change of name, title or address

Address after: new jersey

Patentee after: Qiubi Munster pharmaceutical limited liability company

Address before: Massachusetts, USA

Patentee before: Hydra Biosciences Inc

C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: Luzern, Switzerland

Patentee after: Qiubi Munster pharmaceutical limited liability company

Address before: new jersey

Patentee before: Qiubi Munster pharmaceutical limited liability company